Oklo (OKLO) Q4 2025 Earnings Call Transcript

Oklo completed a $1.5B ATM program in January 2026, raising $1.182B net and ended 2025 with $1.4B in cash and marketable securities, materially strengthening liquidity. Management reported a 2025 operating loss of $139.3M (including $41.8M in stock-based comp), adjusted cash used in operations of $69.2M (within 2025 guidance), and raised 2026 operating cash use guidance to $80–100M and investing cash guidance to $350–450M. The company executed a prepayment agreement with Meta to support up to a 1.2GW Aurora campus (Phase 1 = 150MW targeted ~2030), has begun construction at Aurora-INL, A3F and Groves, and hit multiple DOE/NRC milestones (OTA, NSDA, NRC materials license), with Groves targeting criticality on July 4. These financing, commercial and regulatory developments materially de-risk near-term execution while signaling accelerated capital deployment across power, fuel and isotope business units.

Analysis

Oklo’s vertically integrated play creates optionality that incumbents can’t easily replicate: owning fuel, fabrication, power and isotope pathways converts what would be single-purpose capex into multiple monetizable outputs, lowering the effective payback hurdle for each project. The real competitive lever is learning-by-building — teams that convert DOE-authorized prototypes into repeatable NRC-compliant products will lower unit cost and calendar risk for follow-ons, and that advantage compounds because contractors and commodity suppliers will orient around the faster-moving platform.

Second-order winners are non‑traditional nuclear suppliers (civil contractors, industrial gas and conventional steam/turbomachinery vendors) that can scale capacity without the regulatory overhead of LWR OEMs; losers are providers rooted in legacy LWR supply chains whose pricing power weakens as buyers adopt simpler commodity specifications. The primary near-term catalysts to watch are licensing conversion milestones, fuel allocation decisions, and the first commercial offtake contractual firming — each can re-rate execution risk within 3–18 months. Tail risks that would reverse the trajectory are a tightening of HALEU/plutonium access, a change in NRC conversion rules that reintroduces multi‑year uncertainty, or an abrupt pullback in project finance availability as rates rise.

Consensus is underweight dilution and timetable slippage risk while overvaluing ‘de‑risking’ from a single strategic prepayment; investors should treat commercial prepayments as contingent project anchoring, not a full removal of execution risk. That asymmetry creates trade opportunities: long optionality for binary execution upside (milestone-driven) plus hedges for construction/regulatory outcomes. Manage position sizing tightly — this is a high-idiosyncratic-volatility name best sized as a tactical, milestone‑linked allocation rather than a core holding.

Key Decisions for Investors

• OKLO tactical long convexity: Buy Jan‑2028 LEAP call options (12–20 month horizon) sized at 0.5–1.5% of portfolio notional; fund by selling shorter‑dated OTM calls (6–12 month) to create a call spread. R/R: asymmetric upside (3x+ if DOE/NRC milestones and test‑reactor criticality occur on schedule) vs. limited premium loss if milestones slip.
• OKLO equity with downside protection: Acquire OKLO stock at current levels and purchase a 12‑month 40% OTM put while selling a 12‑month 15–25% OTM call to finance (collar). Timeframe: 12 months. R/R: limits downside to ~‑40% while preserving ~+20–30% upside if commercialization cadence accelerates.
• META optionality play: Allocate a small sizing (0.5–1% portfolio) to 2‑year META calls or LEAPs to capture optional upside from repeatable large‑buyer PPA frameworks. R/R: low funded cost for exposure to corporate demand for bespoke baseload PPAs; downside capped at option premium.
• Banks / project‑finance tail exposure: Buy 9–18 month GS or BAC call spreads (small tactical position) to capture fee and lending upside if project finance for first commercial campuses accelerates. R/R: modest upside if project finance markets re‑open for advanced nuclear; downside limited to premium — use as a macro‑hedge against broader project‑execution optimism.